Skip to main content
SpringerLink
Log in

Role of Insulin-Like Growth Factor Receptors in Cancer Signaling

  • Chapter
  • First Online:
Predictive Biomarkers in Oncology

  • 2656 Accesses

Abstract

The insulin-like growth factor signaling system has been implicated in cancer etiology, progression, and metastasis. This signaling system involves a network of highly related ligands and receptors. Targeting of this system is complex; multiple receptors, including the insulin receptor, are involved. Further, holo- and hybrid receptors must be considered when considering therapeutic strategies. This review will evaluate the signaling pathways mediated by this system.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505–18.

    Article  CAS  PubMed  Google Scholar 

  2. Leroith D, Kavsan VM, Koval AP, Roberts CT. Phylogeny of the insulin-like growth factors (IGFs) and receptors – a molecular approach. Mol Reprod Dev. 1993;35(4):332–8.

    Article  CAS  PubMed  Google Scholar 

  3. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3(70):70ra13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Perks CM, Holly JM. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia. 2008;13(4):455–69.

    Article  PubMed  Google Scholar 

  5. Krywicki RF, Yee D. The insulin-like growth factor family of ligands, receptors, and binding proteins. Breast Cancer Res Treat. 1992;22(1):7–19.

    Article  CAS  PubMed  Google Scholar 

  6. Yee D. A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res. 2015;21(4):667–9.

    Article  CAS  PubMed  Google Scholar 

  7. Ekyalongo RC, Yee D. Revisiting the IGF-1R as a breast Cancer target. NPJ Precis Oncol. 2017;1:14.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14:329–41.

    Article  CAS  PubMed  Google Scholar 

  9. White MF. IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity. Diabetes Obes Metab. 2014;16(Suppl 1):4–15.

    Article  CAS  PubMed  Google Scholar 

  10. Gradishar WJ, Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, et al. Clinical and translational results of a phase II, randomized trial of an anti-IGF-1R (cixutumumab) in women with breast cancer that progressed on endocrine therapy. Clin Cancer Res. 2016;22(2):301–9.

    Article  CAS  PubMed  Google Scholar 

  11. Iams WT, Lovly CM. Molecular pathways: clinical applications and future direction of insulin-like growth factor-1 receptor pathway blockade. Clin Cancer Res. 2015;21(19):4270–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Becker MA, Ibrahim YH, Oh AS, Fagan DH, Byron SA, Sarver AL, et al. Insulin receptor substrate adaptor proteins mediate prognostic gene expression profiles in breast cancer. PLoS One. 2016;11(3):e0150564.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009;27(34):5800–7.

    Article  CAS  PubMed  Google Scholar 

  14. Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL 3rd, Giguere JK, et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Investig New Drugs. 2005;23(5):485–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA

    Douglas Yee

Authors
  1. Douglas Yee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas Yee .

Editor information

Editors and Affiliations

  1. Department of Pathology and Lab Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

    Sunil Badve

  2. Targos Inc., Issaquah, WA, USA

    George Louis Kumar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yee, D. (2019). Role of Insulin-Like Growth Factor Receptors in Cancer Signaling. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-95228-4_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-95227-7

  • Online ISBN: 978-3-319-95228-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation